Abstract:There is intense interest about whether modulating gut microbiota can impact systemic metabolism. We investigated the safety of weekly oral fecal microbiota transplantation (FMT) capsules from healthy lean donors and their ability to alter gut microbiota and improve metabolic outcomes in patients with obesity.FMT-TRIM was a 12-week double-blind randomized placebo-controlled pilot trial of oral FMT capsules performed at a single US academic medical center. Between August 2016 and April 2018, we randomized 24 adults with obesity and mild–moderate insulin resistance (homeostatic model assessment of insulin resistance [HOMA-IR] between 2.0 and 8.0) to weekly healthy lean donor FMT versus placebo capsules for 6 weeks. The primary outcome, assessed by intention to treat, was change in insulin sensitivity between 0 and 6 weeks as measured by hyperinsulinemic euglycemic clamps. Additional metabolic parameters were evaluated at 0, 6, and 12 weeks, including HbA1c, body weight, body composition by dual-energy X-ray absorptiometry, and resting energy expenditure by indirect calorimetry. Fecal samples were serially collected and evaluated via 16S V4 rRNA sequencing. Our study population was 71% female, with an average baseline BMI of 38.8 ± 6.7 kg/m2 and 41.3 ± 5.1 kg/m2 in the FMT and placebo groups, respectively. There were no statistically significant improvements in insulin sensitivity in the FMT group compared to the placebo group (+5% ± 12% in FMT group versus −3% ± 32% in placebo group, mean difference 9%, 95% CI −5% to 28%, p = 0.16). There were no statistically significant differences between groups for most of the other secondary metabolic outcomes, including HOMA-IR (mean difference 0.2, 95% CI −0.9 to 0.9, p = 0.96) and body composition (lean mass mean difference −0.1 kg, 95% CI −1.9 to 1.6 kg, p = 0.87; fat mass mean difference 1.2 kg, 95% CI −0.6 to 3.0 kg, p = 0.18), over the 12-week study. We observed variable engraftment of donor bacterial groups among FMT recipients, which persisted throughout the 12-week study. There were no significant differences in adverse events (AEs) (10 versus 5, p = 0.09), and no serious AEs related to FMT. Limitations of this pilot study are the small sample size, inclusion of participants with relatively mild insulin resistance, and lack of concurrent dietary intervention.Weekly administration of FMT capsules in adults with obesity results in gut microbiota engraftment in most recipients for at least 12 weeks. Despite engraftment, we did not observe clinically significant metabolic effects during the study.ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT02530385">NCT02530385</a>.

Feasibility of fecal microbiota transplantation via oral gavage to safely alter gut microbiome composition in marmosets

Developing the Common Marmoset as a Translational Geroscience Model to Study the Microbiome and Healthy Aging

Impact of diet change on the gut microbiome of common marmosets (Callithrix jacchus)

Comprehensive effects of fecal microbiota transplantation on cynomolgus macaques across various fecal conditions

Procedures for Fecal Microbiota Transplantation in Murine Microbiome Studies

Fecal microbiota transplantation from Suncus murinus, an obesity-resistant animal, to C57BL/6NCrSIc mice, and the antibiotic effects in the approach

Fecal Microbiota Transplantation Donor and Dietary Fiber Intervention Collectively Contribute to Gut Health in a Mouse Model

Fecal microbiota transplantation in a rodent model of short bowel syndrome: A therapeutic approach?

Evaluating rectal swab collection method for gut microbiome analysis in the common marmoset (Callithrix jacchus)

Antibiotic-induced gut dysbiosis elicits gut-brain axis relevant multi-omic signatures and behavioral and neuroendocrine changes in a nonhuman primate model

Fecal microbiota transplantation alters gut phage communities in a clinical trial for obesity

Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans

Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns

Preliminary evidence for developing safe and efficient fecal microbiota transplantation as potential treatment for aged related cognitive impairments

Fecal Microbiota Transplantation: An Update on Clinical Practice

Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: A pilot randomized controlled trial

Effect of fecal microbiota transplantation route of administration on gut colonization and host response in preterm pigs

Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial

Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?

Evaluation of the safety and efficacy of fecal microbiota transplantations in bottlenose dolphins ( Tursiops truncatus ) using metagenomic sequencing

Group membership, not diet, structures the composition and functional potential of the gut microbiome in a wild primate